tocilizumab - versus control - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.85 [0.64, 1.12]< 117%13 studies (13/-)88.0 %some concernlow moderatecrucial-
death or transfer to ICU 0.97 [0.50, 1.88]< 10%1 study (1/-)53.6 %lownot evaluable highcrucial-
deaths 0.85 [0.77, 0.93]< 10%20 studies (20/-)100.0 %some concernlow moderatecrucial-
deaths (time to event analysis only) 0.93 [0.71, 1.21]< 16%4 studies (4/-)71.2 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.76 [0.56, 1.05]< 116%5 studies (5/-)95.1 %some concernnot evaluable moderateimportant-
clinical improvement 1.26 [1.04, 1.52]> 136%5 studies (5/-)99.1 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.19 [0.81, 1.75]> 10%1 study (1/-)81.0 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.15 [0.90, 1.47]> 10%1 study (1/-)86.8 %some concernnot evaluable moderateimportant-
death or ventilation 0.83 [0.72, 0.96]< 117%7 studies (7/-)99.4 %some concernnot evaluable moderateimportant-
hospital discharge 1.05 [0.88, 1.25]> 113%2 studies (2/-)70.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.76 [0.54, 1.09]< 10%4 studies (4/-)93.4 %some concernnot evaluable moderateimportant-
ICU admission 0.85 [0.49, 1.49]< 157%3 studies (3/-)71.2 %some concernnot evaluable moderatenon important-
recovery 0.64 [0.14, 2.92]> 10%1 study (1/-)28.3 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.91 [0.72, 1.15]< 10%7 studies (7/-)78.5 %some concernserious moderateimportant-
adverse events 1.57 [0.96, 2.58]< 169%5 studies (5/-)3.6 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.